Document is current
Any future updates will be listed below
-
Authors
Nayfach, Stephen https://orcid.org/0000-0003-4625-4164
Bhatnagar, Aadyot
Novichkov, Andrey
Kim, Nahye
Hoffnagle, Alexander M.
Hussain, Riffat
Estevam, Gabriella O.
Hill, Emily
Ruffolo, Jeffrey A. https://orcid.org/0000-0002-3385-9191
Silverstein, Rachel A.
Gallagher, Joseph
Kleinstiver, Benjamin P. https://orcid.org/0000-0002-5469-0655
Meeske, Alexander J.
Cameron, Peter
Madani, Ali https://orcid.org/0000-0002-3092-1295
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 19 December 2025
First Online: 2 February 2026
Competing interests
: S.N., A.B., A.N., A.M.H., R.H., G.O.E., E.H., J.A.R., J.G., A.J.M., P.C. and A.M. are current or former employees, contractors or executives of Profluent Bio and may hold shares in Profluent Bio. R.A.S. and B.P.K. are inventors on patents or patent applications filed by Mass General Brigham (MGB) that describe HT-PAMDA or genome-engineering technologies related to the current study. B.P.K. is a consultant for Novartis Venture Fund, Foresite Labs, Generation Bio and Jumble Therapeutics and is on the scientific advisory boards of Life Edit Therapeutics and Prime Medicine. B.P.K. has a financial interest in Prime Medicine. B.P.K.’s interests were reviewed and are managed by MGH and MGB in accordance with their conflict-of-interest policies. The remaining authors declare no competing interests.
